AstraZeneca said Monday that its two immunotherapy cancer drugs, when combined with chemotherapy, slowed the progression of late-stage non-small cell lung cancer compared to chemotherapy alone.
The result comes just six days after Bristol-Myers Squibb reported similar findings with its own immunotherapy drugs and will likely lead to speculation as to whether Merck can hold onto its dominance in lung cancer with its treatment, Keytruda. Both data releases included only preliminary and incomplete data for investors, with full scientific results to follow in the future.
AstraZeneca also said that, in the same study, the combination of its Imfinzi, which is roughly similar to Keytruda, with chemotherapy was also better than chemotherapy alone.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect